Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Norvasc · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | single-capsule of fixed dosed combination (FDC) of amlodipine 5 mg / bisoprolol fumarate 5 mg / perindopril arginine 5 mg |
| Group B | ACTIVE_COMPARATOR | Free triple therapy of amlodipine 5 mg + bisoprolol fumarate 5 mg + perindopril arginine 5 mg, given concomitantly |
| Name | Type | Description |
|---|---|---|
| Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg | COMBINATION_PRODUCT | 1 capsule/day Oral administration |
| Norvasc 5mg tablet | DRUG | Norvasc (amlodipine) 5mg, 1 tablet/day |
| Concor 5mg tablet | DRUG | Concor (bisoprolol fumarate) 5mg, 1 tablet/day |
| Coversyl 5mg tablet | DRUG | Coversyl (perindopril arginine) 5mg, 1 tablet/day |
Selection criteria: * Men or women of any ethnic origin ≥18 years old who signed Informed consent form. * Patients with uncontrolled hypertension defined by SBP ≥140 and \< 160 mmHg and DBP ≥90 and \< 100 mmHg already treated by anti-hypertensive monotherapy at maximal dose or either by a dual ther...
Norvasc is used for the treatment of essential hypertension, a condition of persistently high blood pressure with no identifiable secondary cause. It is a small molecule cardiovascular therapy being developed as a fixed-dose combination in capsule form for patients whose blood pressure is not adequately controlled.
Norvasc is being developed by Tango Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker TNGX. The company is conducting clinical research on this drug for the treatment of essential hypertension.
Norvasc is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under clinical investigation for essential hypertension.
Norvasc has one completed Phase 3 clinical trial registered under NCT05288400. This trial evaluated the efficacy and safety of a fixed-dose combination of amlodipine 5mg, bisoprolol fumarate 5mg, and perindopril arginine 5mg compared to free monotherapy in patients with uncontrolled essential hypertension.
Norvasc is a fixed-dose combination that includes amlodipine 5mg, bisoprolol fumarate 5mg, and perindopril arginine 5mg. It is not the same as amlodipine alone, as it combines three active ingredients in a single capsule for the treatment of essential hypertension.
Norvasc combines three antihypertensive agents: amlodipine, a calcium channel blocker; bisoprolol, a beta-blocker; and perindopril, an ACE inhibitor. These agents work through complementary mechanisms to lower blood pressure in patients with essential hypertension.